Priority 11 from the Psoriasis PSP

UNCERTAINTY: Are oral and biological treatments for psoriasis safe to use for people with psoriasis or their partner if they are trying to have a baby, and are they safe to use during pregnancy? (JLA PSP Priority 11)
Overall ranking 11
JLA question ID 0072/11
Explanatory note Not available for this PSP

Pottinger, 2018 This systematic review concluded that the potential effect of biologics on pregnancy outcomes specifically in women with psoriasis has not been adequately studied to quantify accurately.  Data on use in other indications is limited.  Women of child-bearing potential should be advised routinely to use regular contraception; however, when planning conception the risks and benefits of continuing vs. stopping therapy should be discussed on a case-by-case basis.  To address the clinical uncertainty, large disease-matched cohort studies are required, taking into account potential confounders such as disease activity, concomitant therapies and maternal demographics.  Psoriasis-specific pharmacovigilance registries, for example the British Association of Dermatologist Biologics Intervention Register (BADBIR) in collaboration with others via the European Psoriasis Registry Network (PSONET), provide opportunity to collate such data.

Health Research Classification System category Skin
Extra information provided by this PSP
Original uncertainty examples What is the best treatment for pregnant women with psoriasis?
Submitted by 6 uncertainties were submitted around this question
PSP information
PSP unique ID 0072
PSP name Psoriasis
Total number of uncertainties identified by this PSP. 55  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 17 September 2018